← Back to Search

Olympus VE2 NIR Imaging System for Lung Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up during surgery
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved

Summary

This trial tests a new imaging system that helps surgeons see blood flow during certain cancer surgeries by using a special dye. It targets patients with esophageal and lung cancers to improve surgical outcomes. The system works by highlighting blood flow with a special light, making it easier for surgeons to perform precise operations. The dye has been used in various clinical applications, including cancer surgeries, to help visualize blood flow and tumor margins.

Eligible Conditions
  • Lung Cancer
  • Esophageal Lesion

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~during surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and during surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To utilize NIR intraoperative imaging with the Olympus VE2 NIR Imaging System for esophagectomy patients.
To utilize NIR intraoperative imaging with the Olympus VE2 NIR Imaging System for segmentectomy patients.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Group I: During Minimally Invasive Pulmonary Segmentectomy (Group 2)Experimental Treatment2 Interventions
Group II: During Minimally Invasive Esophagectomy (Group 1)Experimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Indocyanine green
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,014 Previous Clinical Trials
13,309,386 Total Patients Enrolled
OlympusIndustry Sponsor
20 Previous Clinical Trials
3,274 Total Patients Enrolled
~9 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top